Susannah Streeter and Philippe Wolgen, CEO of the CLINUVEL Group, discuss drug development, the impact of capital markets, the redistribution of profits, and more.
Part two of three focuses on the investment required to develop novel drugs, how CLINUVEL is differentiating itself from other biotech companies, and the effects of capital markets on the valuation of a life science company such as CLINUVEL.
Stay tuned for part 3.
In case you missed it, Part 1 focuses on the Company’s approach to navigating shifting markets and unexpected events, and the commercialisation of CLINUVEL’s lead product, including interactions with England’s National Institute for Health and Care Excellence (NICE) and a landmark decision in 2017. Watch Part 1 here.